Compare ClearPoint Neuro Inc (CLPT) vs Iron Mountain Inc (IRM) Price & Performance

ClearPoint Neuro (CLPT) trades at $16.51, down 5.66% on the day, with a bullish technical signal from moving averages but negative profitability. The company reported record Q1 2026 revenue of $36.97M with 25% organic device growth, though it missed EPS estimates with a $0.32 loss. Recent FDA clearance for the Velocity Alpha surgical drill and a partnership with Sungkyunkwan University highlight expansion efforts in neurosurgical navigation and drug delivery.

Outlook remains speculative with 100% analyst buy ratings anticipating gene therapy commercialization upside, but high execution and regulatory risks persist amid consistent losses and negative margins. The stock's valuation at 11.31x sales reflects growth expectations, yet cash burn from operations requires careful monitoring of financing sustainability.

Iron Mountain (IRM) trades at $122.37, up 0.72% on the day, showing strong momentum with a 30.2% gain over three months. The stock is in a bullish technical trend, supported by recent earnings beats and positive analyst sentiment. Revenue growth accelerated to $6.90 billion in 2025, though net margins remain thin at 3.76%. Recent news highlights its data center strength and a $1.5 billion debt offering to fund expansion.

Outlook is cautiously optimistic with a consensus price target of $138.67 offering 13% upside. Risks include high debt levels (debt-to-asset ratio of 79.04% in 2025) and margin pressure. The stock appeals for its growth exposure and dividend yield, but investors should weigh leverage concerns against operational momentum.